Short Interest in Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) Grows By 14.2%

Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) was the target of a large growth in short interest in April. As of April 15th, there was short interest totaling 429,801 shares, a growth of 14.2% from the March 31st total of 376,288 shares. Based on an average daily trading volume, of 43,694 shares, the short-interest ratio is presently 9.8 days. Approximately 9.1% of the shares of the stock are sold short.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Coeptis Therapeutics in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Coeptis Therapeutics Stock Performance

Coeptis Therapeutics stock opened at $14.45 on Friday. The firm has a market capitalization of $89.88 million, a P/E ratio of -4.85 and a beta of -0.09. The stock has a fifty day moving average price of $12.59 and a 200 day moving average price of $13.91. Coeptis Therapeutics has a 52 week low of $6.80 and a 52 week high of $21.41. The company has a current ratio of 4.16, a quick ratio of 4.16 and a debt-to-equity ratio of 0.01.

Coeptis Therapeutics (NASDAQ:ZSQR) last issued its quarterly earnings results on Thursday, March 19th. The company reported ($0.12) earnings per share (EPS) for the quarter. Coeptis Therapeutics had a negative return on equity of 110.89% and a negative net margin of 803.96%.The business had revenue of $0.86 million during the quarter.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC increased its stake in shares of Coeptis Therapeutics by 12.6% during the 4th quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock valued at $600,000 after acquiring an additional 4,721 shares during the last quarter. State Street Corp increased its stake in shares of Coeptis Therapeutics by 35.0% during the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock valued at $382,000 after acquiring an additional 6,962 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of Coeptis Therapeutics during the 4th quarter valued at about $259,000. Yorkville Advisors Global LP acquired a new position in shares of Coeptis Therapeutics during the 3rd quarter valued at about $140,000. Finally, Steward Partners Investment Advisory LLC increased its stake in shares of Coeptis Therapeutics by 100.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock valued at $71,000 after acquiring an additional 2,500 shares during the last quarter. Institutional investors and hedge funds own 13.88% of the company’s stock.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.